Novavax (NASDAQ: NVAX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 2.690 | 2.560 | -0.1300 | ||||
REV | 845.200M | 703.971M | -141.229M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Novavax (NASDAQ: NVAX) through any online brokerage.
Other companies in Novavax’s space includes: Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT) and Neurocrine Biosciences (NASDAQ:NBIX).
The latest price target for Novavax (NASDAQ: NVAX) was reported by Cantor Fitzgerald on Wednesday, June 8, 2022. The analyst firm set a price target for 168.00 expecting NVAX to rise to within 12 months (a possible 175.45% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Novavax (NASDAQ: NVAX) is $60.99 last updated Today at July 5, 2022, 5:35 PM UTC.
There are no upcoming dividends for Novavax.
Novavax’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Novavax.
Novavax is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.